| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,
* Hematological Sciences,
Musculoskeletal Research Group, and
Dermatological Sciences, Institute of Cellular Medicine, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, United Kingdom
Bone marrow mesenchymal stem cells (MSC) have potent immunosuppressive properties and have been advocated for therapeutic use in humans. The nature of their suppressive capacity is poorly understood but is said to be a primitive stem cell function. Demonstration that adult stromal cells such as fibroblasts (Fb) can modulate T cells would have important implications for immunoregulation and cellular therapy. In this report, we show that dermal Fb inhibit allogeneic T cell activation by autologously derived cutaneous APCs and other stimulators. Fb mediate suppression through soluble factors, but this is critically dependent on IFN-
from activated T cells. IFN- induces IDO in Fb, and accelerated tryptophan metabolism is at least partly responsible for suppression of T cell proliferation. T cell suppression is reversible, and transient exposure to Fb during activation reprograms T cells, increasing IL-4 and IL-10 secretion upon restimulation. Increased Th2 polarization by stromal cells is associated with amelioration of pathological changes in a human model of graft-vs-host disease. Dermal Fb are highly clonogenic in vitro, suggesting that Fb-mediated immunosuppression is not due to outgrowth of rare MSC, although dermal Fb remain difficult to distinguish from MSC by phenotype or transdifferentiation capacity. These results suggest that immunosuppression is a general property of stromal cells and that dermal Fb may provide an alternative and accessible source of cellular therapy.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This work was supported by Action Medical Research United Kingdom (RTF1155), Leukaemia Research Fund United Kingdom (06016), and European Commission (MRTN-CT-2004-512253 "TRANSNET").
2 C.M.U.H. and M.P.C. jointly supervised this research.
3 Address correspondence and reprint requests to Dr. Matthew P. Collin, Hematological Sciences, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, U.K. E-mail address: matthew.collin{at}ncl.ac.uk
4 Abbreviations used in this paper: BM, bone marrow; MSC, mesenchymal stem cell; DC, dendritic cell; moDC, monocyte-derived DC; GVHD, graft-vs-host disease; Fb, fibroblast; CFU-F, fibroblast CFU; LC, Langerhans cell; 1-MT, 1-methyl-L- tryptophan.
This article has been cited by other articles:
|
|
 |
|
  M. E.J. Reinders, W. E. Fibbe, and T. J. Rabelink Multipotent mesenchymal stromal cell therapy in renal disease and kidney transplantation Nephrol. Dial. Transplant., October 26, 2009; (2009) gfp552v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Fallarino, G. Luca, M. Calvitti, F. Mancuso, C. Nastruzzi, M. C. Fioretti, U. Grohmann, E. Becchetti, A. Burgevin, R. Kratzer, et al. Therapy of experimental type 1 diabetes by isolated Sertoli cell xenografts alone J. Exp. Med., October 26, 2009; 206(11): 2511 - 2526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Huys, F. Van Hauwermeiren, L. Dejager, E. Dejonckheere, S. Lienenklaus, S. Weiss, G. Leclercq, and C. Libert Type I interferon drives tumor necrosis factor-induced lethal shock J. Exp. Med., August 31, 2009; 206(9): 1873 - 1882. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Bocelli-Tyndall, L Bracci, S Schaeren, C Feder-Mengus, A Barbero, A Tyndall, and G C Spagnoli Human bone marrow mesenchymal stem cells and chondrocytes promote and/or suppress the in vitro proliferation of lymphocytes stimulated by interleukins 2, 7 and 15 Ann Rheum Dis, August 1, 2009; 68(8): 1352 - 1359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. S. Stappenbeck and H. Miyoshi The Role of Stromal Stem Cells in Tissue Regeneration and Wound Repair Science, June 26, 2009; 324(5935): 1666 - 1669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Maby-El Hajjami, P. Ame-Thomas, C. Pangault, O. Tribut, J. DeVos, R. Jean, N. Bescher, C. Monvoisin, J. Dulong, T. Lamy, et al. Functional Alteration of the Lymphoma Stromal Cell Niche by the Cytokine Context: Role of Indoleamine-2,3 Dioxygenase Cancer Res., April 1, 2009; 69(7): 3228 - 3237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Haniffa, M. P. Collin, C. D. Buckley, and F. Dazzi Mesenchymal stem cells: the fibroblasts' new clothes? Haematologica, February 1, 2009; 94(2): 258 - 263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tapp, E. N. Hanley Jr., J. C. Patt, and H. E. Gruber Adipose-Derived Stem Cells: Characterization and Current Application in Orthopaedic Tissue Repair Experimental Biology and Medicine, January 1, 2009; 234(1): 1 - 9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Zalaudek, A. A. Marghoob, A. Scope, B. Leinweber, G. Ferrara, R. Hofmann-Wellenhof, G. Pellacani, H. P. Soyer, and G. Argenziano Three Roots of Melanoma Arch Dermatol, October 1, 2008; 144(10): 1375 - 1379. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Karlsson, S. Samarasinghe, L. M. Ball, B. Sundberg, A. C. Lankester, F. Dazzi, M. Uzunel, K. Rao, P. Veys, K. Le Blanc, et al. Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses Blood, August 1, 2008; 112(3): 532 - 541. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
